Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are
risk-stratified using a number of features including age at diagnosis, disease stage, tumor …

PURPOSE Treatment planning for children with neuroblastoma requires accurate
assessment of prognosis. The most recent Children's Oncology Group (COG) risk …

PURPOSE In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively
activated through activating point mutations or genomic amplification. We studied ALK …

For children with neuroblastoma, the likelihood of cure varies widely according to age at
diagnosis, disease stage, and tumor biology. Treatments are tailored for children with this …

PRIMAGE is one of the largest and more ambitious research projects dealing with medical
imaging, artificial intelligence and cancer treatment in children. It is a 4-year European …

Given the biological and clinical heterogeneity of neuroblastoma, risk stratification is vital to
determining appropriate treatment. Historically, most patients with high‐risk neuroblastoma …

Background Long‐term outcome remains poor for children with high‐risk neuroblastoma
(five‐year overall survival [OS]∼ 50%). Our objectives were to (a) identify prognostic …

Neuroblastoma is the most common extracranial pediatric solid tumor with a heterogeneous
clinical course, ranging from spontaneous regression to metastatic disease and death …

PURPOSE In 2006, Children's Oncology Group (COG) reclassified subgroups of toddlers
diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for …